Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Sangamo Therapeutics Jumped Higher Today

By Brian Orelli, PhD - Feb 28, 2020 at 5:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech secured another big partner.

What happened

Shares of Sangamo Therapeutics (SGMO 8.76%) closed up 28% on Friday after the biotech announced a deal with Biogen (BIIB 1.27%) to develop up to 12 drugs using Sangamo's proprietary zinc finger protein technology.

So what

The deal includes ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, and a third drug for an undisclosed neuromuscular disease. Biogen also has the option to nominate up to nine additional neurological disease targets over the next five years.

For each drug, Sangamo will perform the early research before handing over the reigns to Biogen, which will develop and commercialize the drugs. Sangamo will manufacture the drug used in the initial clinical trials for the first three drugs, at which point Biogen will take over manufacturing duties.

Scientist working in a lab

Image source: Getty Images.

Biogen is paying $350 million upfront to Sangamo, with $125 million as a license fee payment and $225 million as an equity investment. Sangamo is eligible for up to $2.37 billion in milestone payments, including up to $925 million in preapproval milestone payments and up to $1.445 billion in sales-based milestone payments. The biotech is also eligible for high-single-digit to sub-teen double-digit royalties on sales of any drugs that make it through the marathon of drug development.

Now what

This is clearly a great deal for Sangamo, with plenty of up-front cash to help pay for its pipeline of other drugs. Investors just need to keep in mind that drugs from this deal are still preclinical, and the rest of Sangamo's pipeline is all relatively young, with no drugs in phase 3 development.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sangamo Therapeutics Stock Quote
Sangamo Therapeutics
SGMO
$6.33 (8.76%) $0.51
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$220.99 (1.27%) $2.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.